| Host |
Rabbit |
| Klon |
CAL10 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
CC1 |
| Positivkontrolle |
Lung adenocarcinoma, tonsil |
| Verdünnung |
- |
| Isotyp |
IgG1 |
| Verdünnung |
Peptide corresponding to the region within human PD-L1 |
| Lokalisation |
Cell membrane, cytoplasm |
PD-L1 (CD274)
|
Biocare Medical |
CAL10 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3171G |
-
|
| Host |
Mouse |
| Klon |
8003 (99/12) |
| Format |
Purified |
| Methode |
EL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Purified human Pepsinogen I |
Pepsinogen I
|
Zytomed Systems GmbH |
8003 (99/12) |
200 µg |
Purified |
RUO |
616-0101 |
-
|
| Host |
Mouse |
| Klon |
5B10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Spleen |
| Verdünnung |
1:10 - 1:20 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Recombinant protein corresponding to an external region of the C-terminus of the perforin molecule |
| Lokalisation |
Cytoplasm |
Perforin
|
Diagnostic Biosystems |
5B10 |
1 ml |
Concentrate |
CE/IVD |
MOB555 |
-
|
| Host |
Mouse |
| Klon |
5B10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Spleen |
| Verdünnung |
1:10 - 1:20 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Recombinant protein corresponding to an external region of the C-terminus of the perforin molecule |
| Lokalisation |
Cytoplasm |
Perforin
|
Diagnostic Biosystems |
5B10 |
0.1 ml |
Concentrate |
CE/IVD |
MOB555-01 |
-
|
| Host |
Mouse |
| Klon |
5B10 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Spleen |
| Verdünnung |
1:10 - 1:20 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Recombinant protein corresponding to an external region of the C-terminus of the perforin molecule |
| Lokalisation |
Cytoplasm |
Perforin
|
Diagnostic Biosystems |
5B10 |
0.5 ml |
Concentrate |
CE/IVD |
MOB555-05 |
-
|
| Host |
Mouse |
| Klon |
5B10 |
| Format |
ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Spleen |
| Verdünnung |
--- |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Recombinant protein corresponding to an external region of the C-terminus of the perforin molecule |
| Lokalisation |
Cytoplasm |
Perforin
|
Diagnostic Biosystems |
5B10 |
6 ml |
ready-to-use |
CE/IVD |
PDM555 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM159 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG /κ |
| Verdünnung |
Recombinant human Perforin protein fragment (around aa 413-552) |
| Lokalisation |
Granular Cytoplasm |
Perforin
|
Zeta Corporation |
ZM159 |
1 ml |
Concentrate |
CE/IVD |
Z2472ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM159 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Spleen. |
| Verdünnung |
- |
| Isotyp |
IgG /κ |
| Verdünnung |
Recombinant human Perforin protein fragment (around aa 413-552) |
| Lokalisation |
Granular Cytoplasm |
Perforin
|
Zeta Corporation |
ZM159 |
7 ml |
Ready-to-use |
CE/IVD |
Z2472MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM159 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG /κ |
| Verdünnung |
Recombinant human Perforin protein fragment (around aa 413-552) |
| Lokalisation |
Granular Cytoplasm |
Perforin
|
Zeta Corporation |
ZM159 |
0.5 ml |
Concentrate |
CE/IVD |
Z2472MS |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM159 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Spleen. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG /κ |
| Verdünnung |
Recombinant human Perforin protein fragment (around aa 413-552) |
| Lokalisation |
Granular Cytoplasm |
Perforin
|
Zeta Corporation |
ZM159 |
0.1 ml |
Concentrate |
CE/IVD |
Z2472MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
not determined |
| Lokalisation |
Nucleus |
Phospho-Histone H3 (pHH3)
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
CP404A |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
not determined |
| Lokalisation |
Nucleus |
Phospho-Histone H3 (pHH3)
|
Biocare Medical |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
CP404C |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Melanoma |
| Verdünnung |
- |
| Isotyp |
not determined |
| Lokalisation |
Nucleus |
Phospho-Histone H3 (pHH3)
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PP404AA |
-
|
| Host |
Rabbit |
| Klon |
BC37 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, melanoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus (mitotic figure) |
Phospho-Histone H3 (pHH3) (RM)
|
Biocare Medical |
BC37 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3130A |
-
|
| Host |
Rabbit |
| Klon |
BC37 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, melanoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus (mitotic figure) |
Phospho-Histone H3 (pHH3) (RM)
|
Biocare Medical |
BC37 |
1 ml |
Concentrate |
CE/IVD |
ACI3130C |
-
|
| Host |
Rabbit |
| Klon |
BC37 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Tonsil, melanoma |
| Verdünnung |
- |
| Isotyp |
Rabbit IgG |
| Lokalisation |
Nucleus (mitotic figure) |
Phospho-Histone H3 (pHH3) (RM)
|
Biocare Medical |
BC37 |
6 ml |
Ready-to-use |
CE/IVD |
API3130AA |
-
|
| Host |
Rabbit |
| Klon |
ZR292 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Neuroblastoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human PHOX2B protein |
| Lokalisation |
Nuclear |
PHOX2B
|
Zeta Corporation |
ZR292 |
1 ml |
Concentrate |
CE/IVD |
Z2730RL |
-
|
| Host |
Rabbit |
| Klon |
ZR292 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Neuroblastoma |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human PHOX2B protein |
| Lokalisation |
Nuclear |
PHOX2B
|
Zeta Corporation |
ZR292 |
7 ml |
Concentrate |
CE/IVD |
Z2730RP |
-
|
| Host |
Rabbit |
| Klon |
ZR292 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Neuroblastoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human PHOX2B protein |
| Lokalisation |
Nuclear |
PHOX2B
|
Zeta Corporation |
ZR292 |
0.5 ml |
Concentrate |
CE/IVD |
Z2730RS |
-
|
| Host |
Rabbit |
| Klon |
ZR292 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Neuroblastoma |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant fragment of human PHOX2B protein |
| Lokalisation |
Nuclear |
PHOX2B
|
Zeta Corporation |
ZR292 |
0.1 ml |
Concentrate |
CE/IVD |
Z2730RT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal+polyclonal+34ßE12 |
| Format |
Ready-to-use |
| Methode |
P |
| Positivkontrolle |
PIN |
| Verdünnung |
- |
| Isotyp |
Rabbit |
| Lokalisation |
p40: NuclearCytokeratin (HMW): CytoplasmicP504S (AMACR): Cytoplasmic |
PIN-5 Cocktail (p40+P504S+Cytokeratin HMW)
|
Diagnostic Biosystems |
polyclonal+polyclonal+34ßE12 |
6 ml |
Ready-to-use |
CE/IVD |
PDR057 |
-
|
| Host |
Mouse |
| Klon |
ZM385 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human full-length POU1F1 protein |
| Lokalisation |
Nucleus |
PIT1
|
Zeta Corporation |
ZM385 |
1 ml |
Concentrate |
CE/IVD |
Z2676ML |
-
|
| Host |
Mouse |
| Klon |
ZM385 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human full-length POU1F1 protein |
| Lokalisation |
Nucleus |
PIT1
|
Zeta Corporation |
ZM385 |
7 ml |
Concentrate |
CE/IVD |
Z2676MP |
-
|
| Host |
Mouse |
| Klon |
ZM385 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human full-length POU1F1 protein |
| Lokalisation |
Nucleus |
PIT1
|
Zeta Corporation |
ZM385 |
0.5 ml |
Concentrate |
CE/IVD |
Z2676MS |
-
|
| Host |
Mouse |
| Klon |
ZM385 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Pituitary |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant human full-length POU1F1 protein |
| Lokalisation |
Nucleus |
PIT1
|
Zeta Corporation |
ZM385 |
0.1 ml |
Concentrate |
CE/IVD |
Z2676MT |
-
|
| Host |
Mouse |
| Klon |
ZM161 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human ALPP protein |
| Lokalisation |
Cell membrane |
PLAP
|
Zeta Corporation |
ZM161 |
1.0 ml |
Concentrate |
CE/IVD |
Z2474ML |
-
|
| Host |
Mouse |
| Klon |
ZM161 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta. |
| Verdünnung |
- |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human ALPP protein |
| Lokalisation |
Cell membrane |
PLAP
|
Zeta Corporation |
ZM161 |
7 ml |
Ready-to-use |
CE/IVD |
Z2474MP |
-
|
| Host |
Mouse |
| Klon |
ZM161 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human ALPP protein |
| Lokalisation |
Cell membrane |
PLAP
|
Zeta Corporation |
ZM161 |
0.5 ml |
Concentrate |
CE/IVD |
Z2474MS |
-
|
| Host |
Mouse |
| Klon |
ZM161 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Placenta. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b /κ |
| Verdünnung |
Recombinant full-length human ALPP protein |
| Lokalisation |
Cell membrane |
PLAP
|
Zeta Corporation |
ZM161 |
0.1 ml |
Concentrate |
CE/IVD |
Z2474MT |
-
|
| Host |
Rabbit |
| Klon |
SP15 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta or Semonima |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant Protein corresponding to human PLAP |
| Lokalisation |
Cell Membrane |
PLAP (Placental Alkaline Phosphatase)
|
Zytomed Systems GmbH |
SP15 |
1 ml |
Concentrate |
RUO |
RBK056 |
-
|
| Host |
Rabbit |
| Klon |
SP15 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Placenta or Semonima |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit IgG |
| Verdünnung |
Recombinant Protein corresponding to human PLAP |
| Lokalisation |
Cell Membrane |
PLAP (Placental Alkaline Phosphatase)
|
Zytomed Systems GmbH |
SP15 |
0.5 ml |
Concentrate |
RUO |
RBK056-05 |
-
|
| Host |
Mouse |
| Klon |
A16-4 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon |
| Verdünnung |
1:25 - 1:100 |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant human PMS2 (C-Terminus) |
| Lokalisation |
Nucleus |
PMS2
|
Zytomed Systems GmbH |
A16-4 |
0.5 ml |
Concentrate |
RUO |
MSK064-05 |
-
|
| Host |
Mouse |
| Klon |
A16-4 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Colon |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 kappa |
| Verdünnung |
Recombinant human PMS2 (C-Terminus) |
| Lokalisation |
Nucleus |
PMS2
|
Diagnostic Biosystems |
A16-4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM171 |
-
|
| Host |
Rabbit |
| Klon |
ZR317 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
A synthetic peptide corresponding to residues |
| Lokalisation |
Nuclear |
PMS2
|
Zeta Corporation |
ZR317 |
1 ml |
Concentrate |
CE/IVD |
Z2621RL |
-
|
| Host |
Rabbit |
| Klon |
ZR317 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
A synthetic peptide corresponding to residues |
| Lokalisation |
Nuclear |
PMS2
|
Zeta Corporation |
ZR317 |
7 ml |
Concentrate |
CE/IVD |
Z2621RP |
-
|
| Host |
Rabbit |
| Klon |
ZR317 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
A synthetic peptide corresponding to residues |
| Lokalisation |
Nuclear |
PMS2
|
Zeta Corporation |
ZR317 |
0.5 ml |
Concentrate |
CE/IVD |
Z2621RS |
-
|
| Host |
Rabbit |
| Klon |
ZR317 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG |
| Verdünnung |
A synthetic peptide corresponding to residues |
| Lokalisation |
Nuclear |
PMS2
|
Zeta Corporation |
ZR317 |
0.1 ml |
Concentrate |
CE/IVD |
Z2621RT |
-
|
| Host |
Mouse |
| Klon |
3F6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Infected Lung |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Alveolar Spaces |
Pneumocystis carinii
|
Diagnostic Biosystems |
3F6 |
1 ml |
Concentrate |
CE/IVD |
MOB091 |
-
|
| Host |
Mouse |
| Klon |
3F6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Infected Lung |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Alveolar Spaces |
Pneumocystis carinii
|
Diagnostic Biosystems |
3F6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB091-01 |
-
|
| Host |
Mouse |
| Klon |
3F6 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Infected Lung |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgM |
| Lokalisation |
Alveolar Spaces |
Pneumocystis carinii
|
Diagnostic Biosystems |
3F6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB091-05 |
-
|
| Host |
Mouse |
| Klon |
3F6 |
| Format |
ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Infected Lung |
| Verdünnung |
--- |
| Isotyp |
Mouse IgM |
| Lokalisation |
Alveolar Spaces |
Pneumocystis carinii
|
Diagnostic Biosystems |
3F6 |
6 ml |
ready-to-use |
CE/IVD |
PDM584 |
-
|
| Host |
Mouse |
| Klon |
D2-40 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Germ cell tumor. |
| Verdünnung |
1:20 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
M2A |
| Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
1.0 ml |
Concentrate |
CE/IVD |
Z2097ML |
-
|
| Host |
Mouse |
| Klon |
D2-40 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Germ cell tumor. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
M2A |
| Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
7 ml |
Ready-to-use |
CE/IVD |
Z2097MP |
-
|
| Host |
Mouse |
| Klon |
D2-40 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Germ cell tumor. |
| Verdünnung |
1:20 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
M2A |
| Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
0.5 ml |
Concentrate |
CE/IVD |
Z2097MS |
-
|
| Host |
Mouse |
| Klon |
D2-40 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Germ cell tumor. |
| Verdünnung |
1:20 - 1:100 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
M2A |
| Lokalisation |
Cytoplasm |
Podoplanin
|
Zeta Corporation |
D2-40 |
0.1 ml |
Concentrate |
CE/IVD |
Z2097MT |
-
|
| Host |
Mouse |
| Klon |
D2-40 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Lymphendothelium |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Diagnostic Biosystems |
D2-40 |
6 ml |
Ready-to-use |
CE/IVD |
PDM558 |
-
|
| Host |
Mouse |
| Klon |
D2-40 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Lymphendothelium |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Diagnostic Biosystems |
D2-40 |
25 ml |
Ready-to-use |
CE/IVD |
PDM558-25 |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM31 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
| Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
1 ml |
Concentrate |
CE/IVD |
Z2338ML |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM31 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
| Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
7 ml |
Ready-to-use |
CE/IVD |
Z2338MP |
-
|
| Host |
Monospecific Mouse |
| Klon |
ZM31 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Mesothelioma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant human Podoplanin (PDPN) protein fragment (around aa 24-126) |
| Lokalisation |
Cytoplasm |
Podoplanin (Lymphatic endothelium marker)
|
Zeta Corporation |
ZM31 |
0.5 ml |
Concentrate |
CE/IVD |
Z2338MS |
-
|